Company Overview
| Stock Name | Simcere Pharma |
|---|---|
| Stock Code | 02096 |
| Company Full Name | To be extracted |
| Industry | 醫療保健 |
| Principal Activities | 主要在中國從事藥品研發、生產和商業化，當中以仿制藥為主，專注治療領域包括腫瘤疾病、中樞神經系統疾病及自身免疫疾病。 |
| Listing Date | 2020-10-27 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國江蘇省南京市玄武區玄武大道699-18號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.simcere.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 13.70 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 41.2% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 1,784,904,500 |
Stock Connect Inclusion
| HK Market Cap | --- |
|---|---|
| Analysis Result | Already included in Stock Connect (both, shenzhen, shanghai) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 10.98 |
|---|---|
| First Day Open | HK$ 11.0 |
| First Day Change | -19.85% |
| First Day Volume | 125444000.0 |
| First Day Turnover | 1369320000.0 |
Use of Proceeds
| Use of Proceeds | 1、約60%（或2,035.4百萬港元）將分配予我們在戰略重點治療領域中選定的在研產品的持續研發； 2、約10%（或339.2百萬港元）將分配予加強我們的銷售及營銷能力； 3、約10%（或339.2百萬港元）將分配予我們于未來幾年投資醫藥或生物技術領域的公司，以拓寬我們的產品組合； 4、約10%（或339.2百萬港元）將分配予償還如下表所示的若干未償還銀行貸款； 5、約10%（或339.2百萬港元）將用作營運資金及其他一般企業用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
Overall Coordinators (3)
Joint Bookrunners (4)
Joint Lead Managers (5)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Hillhouse Funds | 387,504,500 HKD | — | 10.86% | — | 6 months | 2021-04-27 |
| 2 | Jericho Capital Master Fund L.P. | 77,500,900 HKD | — | 2.17% | — | 6 months | 2021-04-27 |
| 3 | Lake Bleu Prime Healthcare Master Fund Limited | 193,745,400 HKD | — | 5.43% | — | 6 months | 2021-04-27 |
| 4 | OrbiMed Funds | 193,745,400 HKD | — | 5.43% | — | 6 months | 2021-04-27 |
| 5 | Sage Partners Master Fund | 77,500,900 HKD | — | 2.17% | — | 6 months | 2021-04-27 |
| 6 | 高新(香港)有限公司 | 310,003,600 HKD | — | 8.68% | — | 6 months | 2021-04-27 |
| 7 | 红土创新国际有限公司 | 232,489,000 HKD | — | 6.51% | — | 6 months | 2021-04-27 |
Directors & Management
| Chairman | 任晉生 |
|---|---|
| Company Secretary | 萬玉山,麥寶文 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 任晉生及關連人士(69.15%) |
|---|
